MRI Should Be Performed in This Patient
No, MRI should not be performed in this 80-year-old man with chronic myeloid leukemia, rising PSA from 6 to 8 ng/mL, no urinary symptoms, and normal DRE, because he has less than 10-15 years of life expectancy and is unlikely to benefit from prostate cancer diagnosis or treatment. 1
Life Expectancy as the Primary Decision Point
The 2024 EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines explicitly state that men with <15 years of life expectancy are unlikely to benefit from any form of early diagnosis 1. At 80 years old with chronic myeloid leukemia (CML), this patient's life expectancy is substantially limited by:
- Age alone: Average life expectancy for an 80-year-old male is approximately 8-9 years
- CML comorbidity: Even with modern tyrosine kinase inhibitor therapy, CML represents a significant competing mortality risk 2
The guidelines emphasize that comorbidity is at least as important as age when determining whether to pursue prostate cancer diagnosis 1.
Why MRI Would Not Change Management
Even if MRI detected clinically significant prostate cancer:
- No curative treatment would be appropriate given his limited life expectancy
- Active surveillance or watchful waiting would be the only reasonable approach regardless of findings
- The PSA rise from 6 to 8 ng/mL is modest and does not suggest aggressive disease requiring urgent intervention
- Normal DRE further reduces concern for locally advanced disease
The Diagnostic Algorithm Does Not Support MRI Here
According to the 2024 guidelines flow diagram 1:
- Initial risk assessment includes PSA, DRE, plus life expectancy, family history, and ethnicity
- Patients are stratified into asymptomatic with >10-15 years life expectancy versus those with shorter life expectancy
- This patient falls into the "individualized follow-up" pathway for symptomatic or limited life expectancy patients, not the diagnostic pathway
When MRI Would Be Appropriate
MRI would be indicated if this patient had:
- Life expectancy >10-15 years (younger age, no significant comorbidities)
- Symptomatic disease requiring palliative intervention decisions
- Very high PSA (>50 ng/mL) or abnormal DRE suggesting locally advanced disease where staging might affect palliative treatment decisions 1
Common Pitfall to Avoid
The reflexive ordering of MRI for any rising PSA represents overdiagnosis and overtreatment. The guidelines specifically warn that breaking the compulsory link between diagnosis and treatment is essential to decrease overtreatment risk 1. In this elderly patient with CML, pursuing MRI would likely lead to:
- Unnecessary anxiety
- Potential cascade of further testing and biopsies
- Detection of indolent cancer that would never affect his survival
- Healthcare resource waste
Recommended Approach
PSA monitoring with clinical assessment is sufficient. If PSA continues rising dramatically or symptoms develop, reassess whether staging imaging would change palliative management decisions. Otherwise, focus medical care on optimizing his CML management and overall quality of life.